Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD

BACKGROUND AND OBJECTIVES: Roxadustat (FG-4592), an oral hypoxia–inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis, regulates iron metabolism, and reduces hepcidin, was evaluated in this phase 2b study for safety, efficacy, optimal dose, and dose frequency in patients with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin J Am Soc Nephrol
Main Authors: Provenzano, Robert, Besarab, Anatole, Sun, Chao H., Diamond, Susan A., Durham, John H., Cangiano, Jose L., Aiello, Joseph R., Novak, James E., Lee, Tyson, Leong, Robert, Roberts, Brian K., Saikali, Khalil G., Hemmerich, Stefan, Szczech, Lynda A., Yu, Kin-Hung Peony, Neff, Thomas B.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Nephrology 2016
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4891748/
https://ncbi.nlm.nih.gov/pubmed/27094610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.06890615
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados